
The Hedgehog inhibitor vismodegib is a standard-of-care agent for patients with locally advanced or metastatic basal cell carcinomas (BCCs), although most will eventually have disease progression. BCCs are among the cancer types with a higher tumour mutational burden and, thus, immune-checkpoint inhibitors might have clinical activity in this setting...
Like
Save
Share